IPP Bureau

IHL Care Launches digital health centre
IHL Care Launches digital health centre

By IPP Bureau - January 21, 2022

First of its kind integrated Heart Health Programme on its Health Station ‘hPod’

SEC recommends regular market approval for Covishield and Covaxin
SEC recommends regular market approval for Covishield and Covaxin

By IPP Bureau - January 20, 2022

However, these won’t be available at the nearest chemist store soon

Dolomite Bio announce launch of cost-effective Bioinformatics service
Dolomite Bio announce launch of cost-effective Bioinformatics service

By IPP Bureau - January 20, 2022

Unlike most data analysis services, Dolomite Bio will accept sample sizes ranging from as little as one sample, to as many as the research project requires

Australia grants provisional registration for Novavax Covid-19 vaccine
Australia grants provisional registration for Novavax Covid-19 vaccine

By IPP Bureau - January 20, 2022

Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia

Zydus receives final approval from USFDA for Vigabatrin tablets
Zydus receives final approval from USFDA for Vigabatrin tablets

By IPP Bureau - January 20, 2022

Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain

Glenmark Specialty S.A. partners with Lotus to commercialise Ryaltris in key Asian markets
Glenmark Specialty S.A. partners with Lotus to commercialise Ryaltris in key Asian markets

By IPP Bureau - January 20, 2022

The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus

VFMCRP receives EU approval for Tavneos for the treatment of ANCA-associated vasculitis
VFMCRP receives EU approval for Tavneos for the treatment of ANCA-associated vasculitis

By IPP Bureau - January 20, 2022

First launches expected in H1 2022

AstraZeneca India appoints Ram Mudaliar as India lead of their CDI division
AstraZeneca India appoints Ram Mudaliar as India lead of their CDI division

By IPP Bureau - January 20, 2022

Ram’s appointment follows the launch of the CDI India division in October 2021.

Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide
Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide

By IPP Bureau - January 20, 2022

Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach

Natco Pharma signs agreement with Medicines Patent Pool
Natco Pharma signs agreement with Medicines Patent Pool

By IPP Bureau - January 20, 2022

This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name

Strides Pharma and subsidiary Universal Corporation enters tie-up with Medicines Patent Pool
Strides Pharma and subsidiary Universal Corporation enters tie-up with Medicines Patent Pool

By IPP Bureau - January 20, 2022

They will commercialize molnupiravir in the international markets

Max Healthcare to add over 300 beds in NCR ties up with Muthoot Hospitals
Max Healthcare to add over 300 beds in NCR ties up with Muthoot Hospitals

By IPP Bureau - January 20, 2022

The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka

CliniSys creates world’s largest diagnostics and lab informatics with recent acquisitions
CliniSys creates world’s largest diagnostics and lab informatics with recent acquisitions

By IPP Bureau - January 19, 2022

CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe

Lupin ties up with Foncoo of China
Lupin ties up with Foncoo of China

By IPP Bureau - January 19, 2022

This is the company’s first partnership arrangement in China

Lonza, Forbion, and BioGeneration to focus on manufacturing of small molecules
Lonza, Forbion, and BioGeneration to focus on manufacturing of small molecules

By IPP Bureau - January 19, 2022

The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space

Latest Stories

Interviews

Packaging